A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance of multidoses of ADV6770 as monotherapy or in combination, in children with childhood absence epilepsy.

Trial Profile

A randomised, active controlled, open-label, 2-way cross-over, multicentre study to investigate the palatability, acceptability, pharmacokinetics, safety and tolerability, and treatment compliance of multidoses of ADV6770 as monotherapy or in combination, in children with childhood absence epilepsy.

Not stated
Phase of Trial: Phase II

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs ADV 6770 (Primary) ; Ethosuximide
  • Indications Absence epilepsy
  • Focus Therapeutic Use
  • Acronyms KIEKIDS A11CS
  • Sponsors Advicenne
  • Most Recent Events

    • 04 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top